GlassScriptPhysician profile
Matthew Shaw Ray
NPI 1275952541
$4,284.10
in general payments reported to CMS, 2019-2025
14 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.94 · 2021: $107 · 2022: $477 · 2023: $934 · 2024: $938 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Consulting Fee: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.51 |
| Consulting Fee | $1,440.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,749.31 | 2023-2025 | |
| Amgen INC. | $330.65 | 2021-2023 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $279.75 | 2022-2025 | |
| Abbott Laboratories | $169.72 | 2023 | Cardiomems |
| Tandem Diabetes Care, INC. | $134.49 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $130.73 | 2022-2023 | Jynarque |
| Baxter Healthcare | $117.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.46 | 2022 | |
| Vifor Pharma, INC. | $81.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.58 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $60.00 | 2024 | |
| Novo Nordisk INC | $21.12 | 2025 | |
| Glaxosmithkline, LLC. | $14.75 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.